About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
April 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Twitter List
Legislative Tracking Tools
Category Archives: Marketing
A Rule of Thumb – Some Tips for Pre-Approval Communications Around Data Milestones
When an investigational product is working its way down the clinical trial path, it is natural for a drug sponsor to want to communicate about its progress. But when it comes to pre-approval communications, there are some caveats, particularly respecting … Continue reading
Posted in Marketing
Comments Off on A Rule of Thumb – Some Tips for Pre-Approval Communications Around Data Milestones
Generics and Pricing, Part II – A Drug, A Price and a Senator
Recently Merck announced a lowering of the price of Zocor (simvastatin) in a move that presumably will put their brand name drug in a competitive position vis a vis an upcoming generic product, just approved by the FDA. This brought … Continue reading
Posted in Marketing, Pricing and Value
1 Comment
A New Day in Public Relations and Pharma Marketing
Related to yesterday’s posting, one of the consequences of the "new environment" of the post-COX-2s is that, because issues involving drug approval are getting more attention from both the public in general and policy makers in particular, the communications issues … Continue reading
Clouds on the Horizon, Part 2
On Friday, I discussed the fact that there are some clouds on the horizon for the image of the pharmaceutical industry as the Medicare Drug Benefit matures. Today, I’m looking further out on the horizon. The Pharmaceutical Research and Manufacturers … Continue reading
Posted in Marketing, Pricing and Value
Comments Off on Clouds on the Horizon, Part 2
Balancing a Diet – Balancing an Ad
The other night while watching the news, during a rare break from pharmaceutical advertising, there was a commercial for a multiple vitamin. The ad extolled the virtues of the product, and then in a little snippet that I almost missed, … Continue reading
Posted in Marketing, Vitamins and Supplements
Comments Off on Balancing a Diet – Balancing an Ad